Who We Are
PhagePro, PBC. is a preclinical Boston-based biotech startup developing phage-based solutions to reduce the burden of antimicrobial resistance in emerging markets. Our team is innovative in our science and vigilant in our R&D approach to designing products for low- and middle-income countries. We recognize that many interventions in the past have failed due to lack of contextualization in the early stages of development. Therefore, we prioritize stakeholder relationships to understand needs and incorporate them into our strategies to increase adoption on a global scale. Using a pragmatic but creative approach to social entrepreneurship, we will create a sustainable business that brings innovation to the communities that need it the most.
Read more about PhagePro’s CEO, Dr. Minmin Yen.
PhagePro strives to build a company grounded in diversity and inclusion. Interwoven into all levels of the company are efforts to provide more leadership opportunities to women and people of color. We believe strongly that as a global health startup, all voices must be heard and integrated to be successful.
Our company is a discovery-driven venture spun out of the Camilli Lab at Tufts University, where Professor Andrew Camilli has studied cholera for over 20 years. Dr. Minmin Yen initiated the proof-of-concept experiments for our lead program, ProphaLytic-Vc (PVC), as a microbiology PhD student in the Camilli Lab and spearheaded the efforts to translate the product from the laboratory into the field. We are committed to using our expertise in microbiology, global health, and social entrepreneurship to grow our team by cultivating relationships with critical partners that will help us build the infrastructure for introducing a new modality of prevention and treatment for bacterial diseases.
